Figure 4 a) Image of dexamethasone PS DDS implant and b) a cross-sectional image of the retina with dexamethasone PS DDS implanted b) Comparator – clinical claim for the proposed medical service Please provide details of how the proposed service is expected to be used, for example is it to replace or substitute a current practice; in addition to, or to augment current practice. Diagnosis of DMO with vision impairment OCT augments other ophthalmic assessments in the diagnosis of DMO and the identification of patients with centre involving DMO for pharmacological treatment. It also provides information on the extent of DMO. The proposed comparison for diagnosis of DMO is: Clinical examination, VA and ophthalmic assessments all form part of the assessment of macular disease. OCT represents an additional ophthalmic assessment. It serves to augment, rather than replace the other ophthalmic assessments. Monitoring of DMO with vision impairment for treatment with dexamethasone PS DDS The proposed comparison for monitoring of DMO is: Comparator to be addressed in the PBAC submission It is proposed that the co-dependent PBAC application will assess the value of standard management of DMO versus the management with the introduction of dexamethasone PS DDS.
Figure 4 a) Image of dexamethasone PS DDS implant and b) a cross-sectional image of the retina with dexamethasone PS DDS implanted b) Comparator – clinical claim for the proposed medical service Please provide details of how the proposed service is expected to be used, for example is it to replace or substitute a current practice; in addition to, or to augment current practice. Diagnosis of DMO with vision impairment OCT augments other ophthalmic assessments in the diagnosis of DMO and the identification of patients with centre involving DMO for pharmacological treatment. It also provides information on the extent of DMO. The proposed comparison for diagnosis of DMO is: Clinical examination, VA and ophthalmic assessments all form part of the assessment of macular disease. OCT represents an additional ophthalmic assessment. It serves to augment, rather than replace the other ophthalmic assessments. Monitoring of DMO with vision impairment for treatment with dexamethasone PS DDS The proposed comparison for monitoring of DMO is: Comparator to be addressed in the PBAC submission It is proposed that the co-dependent PBAC application will assess the value of standard management of DMO versus the management with the introduction of dexamethasone PS DDS.
1377-Optical%20Coherence%20Tomography-ConsultationProtocol_redacted-accessible.docx